A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia

Conditions:   Breast Cancer;   Prostate Cancer;   Pancreatic Cancer;   Acute Myelogenous Leukemia Interventions:   Procedure: Biopsy;   Drug: ABIRATERONE;   Drug: ENZALUTAMIDE;   Drug: VENETOCLAX;   Drug: PALBOCICLIB;   Drug: All-trans Retinoic Acid;   Drug: BORTEZOMIB;   Drug: CABAZITAXEL;   Drug: OXALIPLATIN;   Drug: FLUOROURACIL;   Drug: FOLINIC ACID;   Drug: CARBOPLATIN;   Drug : PANOBINOSTAT;   Drug: VORINOSTAT;   Drug: PEMBROLIZUMAB;   Drug: BEVACIZUMAB;   Drug: IPILIMUMAB;   Drug: NIVOLUMAB;   Drug: EVEROLIMUS;   Drug: SIROLIMUS;   Drug: CELECOXIB;   Drug: OLAPARIB;   Drug: AFATINIB;   Drug: CABOZANTINIB;   Drug: SORAFENIB;   Drug: DASATINIB;   Drug: ERLOTINIB;   Drug: IDELALISIB;   Drug: IMATINIB;   Drug: LENVATINIB;   Drug: PERTUZUMAB;   Drug: PONATINIB;   Drug: RUXOLITINIB;   Drug: SUNITINIB;   Drug: TRAMETINIB;   Drug: VEMURAFENIB Sponsors:   OHSU Knight Cancer Institute;   Oregon Health and Science University;   Prospect Creek Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials